Which symptom is most concerning following paclitaxel treatment for a patient with ovarian cancer?

Following paclitaxel treatment for ovarian cancer, the most concerning symptom is bradycardia. This is significant because paclitaxel can cause cardiovascular side effects, including alterations in heart rate and rhythm. Bradycardia, which refers to an abnormally slow heart rate, can lead to decreased cardiac output and inadequate blood circulation, potentially resulting in serious complications.

Patients undergoing chemotherapy may experience a range of side effects, such as nausea and fatigue, which are generally more common and less immediately life-threatening. While confusion can be a concern and may indicate a range of issues, including metabolic disturbances or neurotoxicity, it does not specifically associate with cardiac function as prominently as bradycardia does in the context of paclitaxel treatment. Identifying bradycardia necessitates prompt assessment and intervention to ensure the patient’s cardiovascular health is maintained.